top of page

Search Results

243 items found for "Ermium Therapeutics"

  • Orion and Peptilogics are pursuing AI-driven drug discovery to explore new functional chemical ...

    are pursuing AI-driven drug discovery to explore new functional chemical space and precision-engineer therapeutics

  • Targeting Intracellular Allosteric Sites in GPCRs

    other GPCR-regulated systems such as free fatty acid receptors (FFARs), now regarded as targets for therapeutic and β-arrestin coupling, enabling the development of biased agonists and antagonists with distinct therapeutic Allosteric modulation is gaining prominence in GPCR therapeutics, with the discovery of an intracellular Biased allosteric modulators can enhance the safety and efficacy of GPCR-targeted therapeutics by selectively

  • 📰 GPCR Weekly News, August 21 to 27, 2023

    GPCR Symposium on 'GPCRs as Therapeutic Modalities'. neutrophil chemoattractant Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics

  • Discovery On Target, October 17-20, 2022, Boston, USA

    and technologies, as well as target validation strategies for the discovery and development of novel therapeutic

  • 📰 GPCR Weekly News, May 27 to June 2, 2024

    tunes mGlu5 receptor function, impacting synaptic transmission Orphan receptor GPR88 as a potential therapeutic the neuropeptide Y4 receptor and its ligand pancreatic polypeptide from a structural, functional, and therapeutic Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies Industry News Structure Therapeutics

  • 📢 Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024

    Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic INV-347 improves metabolic dysfunction in obese mice Aneesh Karatt Vellatt (CSO & Co-Founder, Maxion Therapeutics ) – BioLeader Interview Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK

  • 📰 GPCR Weekly News, September 25 to October 1, 2023

    of traditional Chinese medicine in the treatment of glioblastoma multiforme Industry News Structure Therapeutics Half-Year Financial Results and Exciting Developments at Aelis Farma Ion Channel Drug Developer Maxion Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

  • 📰 GPCR Weekly News, September 18 to 24, 2023

    GPCR Symposium about 'GPCRs as Therapeutic Modalities' rocked it! recommended by NICE for acute migraines Addex mGlu2 NAM Cognition Program Receives €4 Million Grant Confo Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

  • 📰 GPCR Weekly News, January 1 to 7, 2024

    Congratulations to Domain Therapeutics for appointing Michael Gottlieb as Chairman and Dr. of GPCRs in various states Reviews, GPCRs, and more G Protein-coupled Receptors (GPCRs) as Potential Therapeutics modulate engagement of CCR5 by chemokines by removing key electrostatic interactions Industry News Domain Therapeutics

  • 📰 GPCR Weekly News, April 15 to 21, 2024

    GPCRs in Oncology and Immunology Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Deorphanization of G Protein Coupled Receptors (GPCRs): a historical perspective Industry News Addex Therapeutics at the 19th Biopharma Drug Discovery Nexus Salipro Biotech will participate in BioKorea2024 Domain Therapeutics

  • ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships

    ., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide

  • Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells...

    As therapeutic options are limited, novel targets and agents for therapeutic intervention are urgently

  • 📰 Breaking Down the Latest GPCR Discoveries: a Weekly Update (Nov 27-Dec 3, 2023)

    activity, and structural evaluation Flavonoids as G Protein-coupled Receptors Ligands: New Potential Therapeutic back GPCR agonist after GSK changes course All-rounder among receptors inspires drug research Tectonic Therapeutic Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries Carmot Therapeutics

  • Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop ...

    Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic high-quality synthetic DNA using its silicon platform, announced a strategic collaboration to discover therapeutic

  • 📰 GPCR Weekly News, April 3 to 9, 2023

    GPCRs in Neuroscience G protein-coupled receptors (GPCRs) as Potential Therapeutics for Psychiatric Disorders Domain Therapeutics to present three posters at AACR 2023 annual meeting. Biotech Day (April 24 - 25, 2023) NEW ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

  • 📰 GPCR Weekly News, March 20 to 26, 2023

    Industry News Domain Therapeutics was one of the 4 Biotech Trophy nominees at 2023 HealthTech awards. Function Therapeutics has been awarded a Phase 1 SBIR grant from NSF. Function Therapeutics has a new website. Call for GPCR Papers GPCRs: Signal Transduction.

  • 📰 GPCR Weekly News

    Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders GPCRs in Oncology and Immunology Clinical, pathophysiologic, genetic and therapeutic progress in Primary Sosei Heptares and Neurocrine Biosciences won Out-Licensing Deal of the Year from Locust Walk Omass Therapeutics Use Disorders AbbVie recruits a GPCR team in Oxford, buying out a fledgling biotech for $255M+ Domain Therapeutics

  • Amgen to Acquire Chemocentryx for $4 Billion in Cash

    ., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune

  • Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024

    Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Industry News MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3 Certa Therapeutics proteins for biology and health research Innovate UK announced the winners of its Transforming Cancer Therapeutics

  • Unlock the Future of GPCR Science: Breakthroughs and Courses Await | Sep 2 - Sep 8, 2024

    Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic September 2nd to 8th, 2024 Industry News Superluminal Medicines Closes $120 Million Series A Round Domain Therapeutics Heterodimer, TAS1R2/1R3 GPCRs in Neuroscience GPCR-Mediated Natural Products and Compounds: Potential Therapeutic

  • Novo Nordisk moves to strengthen obesity efforts

    Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics

  • Applications of Cryo-EM in small molecule and biologics drug design

    As a result, cryo-EM has begun to make major impacts in bringing critical therapeutics to market. In this review, we discuss recent instructive examples of impacts from cryo-EM in therapeutics design

  • Dr. Josephine (Pina) Cardarelli - Dr. GPCR Podcast

    Pina Cardarelli, CSO of GPCR Therapeutics.

  • 📰 GPCR Weekly News

    future perspectives Non-canonical Golgi-compartmentalized Gβγ signaling: mechanisms, functions, and therapeutic Research Term Of Substance Use Disorder Gabab Positive Allosteric Modulator Discovery Collaboration Domain Therapeutics

  • Navigating the Signaling Network: RTK and GPCR Crosstalk Uncovered

    This knowledge could inform the development of therapeutic strategies aimed at targeting specific phosphorylation These findings enhance our understanding of cellular signaling dynamics and open new avenues for therapeutic

  • Chemokine receptor-targeted drug discovery: progress and challenges

    The therapeutic approaches mainly include small molecule inhibitors, as well as monoclonal antibodies frequency of administration are particularly rigorous for this class, as the majority of potential therapeutic Overall, the future potential lies in using different therapeutic modalities to modulate the stromal

  • Targeting the M1 muscarinic receptor in neurodegenerative disease

    the role of the muscarinic M1 receptor in cognitive and neurodegenerative disorders and the potential therapeutic

  • Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR

    activity without directly competing with ligands, potentially reducing side effects and increasing therapeutic the findings of this study have significant implications for drug design, personalised medicine, and therapeutic

bottom of page